Shaquille O'Neal Shares Experience with Sleep Apnea
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Raising Health Awareness: Basketball legend Shaquille O'Neal partners with Eli Lilly to share his personal journey with moderate obstructive sleep apnea (OSA), aiming to raise public awareness about this health issue affecting approximately 24 million adults in the U.S. and encouraging more individuals to seek medical help.
- Significant Drug Efficacy: Zepbound® (tirzepatide), the first prescription medication for moderate-to-severe OSA, demonstrated in clinical studies that adults using the drug experienced a reduction in average breathing interruptions from 52.9 to 27.6 per hour over 52 weeks, significantly improving sleep quality and daily functioning.
- National Campaign Launch: Lilly has initiated the “Watch This” national campaign, leveraging O'Neal's authentic story across multiple channels to encourage individuals to recognize OSA symptoms and engage in discussions with their doctors, thereby increasing awareness and treatment rates for the condition.
- Community Engagement Plan: O'Neal plans to engage with communities through face-to-face interactions, sharing his struggles with OSA to help more people recognize potential health issues and motivate them to proactively seek medical advice.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1144.680
Low
950.00
Averages
1192
High
1500
Current: 1144.680
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves New Dosing Regimen for EBGLYSS
- New Dosing Regimen: EBGLYSS (lebrikizumab-lbkz) has received FDA approval for a new regimen allowing a single 250 mg injection every eight weeks, reducing the treatment frequency to as few as six maintenance injections per year, significantly enhancing patient quality of life.
- Clinical Data Support: This approval is based on clinical data from the 32-week ADjoin long-term trial, demonstrating that the new dosing regimen maintains safety and efficacy comparable to the every-four-week schedule, ensuring sustained disease control for patients.
- Market Potential: As a first-line biologic treatment for moderate-to-severe atopic dermatitis, EBGLYSS is expected to attract more patients, further solidifying Lilly's market position in dermatological therapies.
- Patient Support Program: Lilly offers co-pay assistance through its EBGLYSS patient support services, ensuring that 94% of commercially insured patients have coverage, reflecting the company's commitment to health equity and affordability for patients.
See More
Shaquille O'Neal Shares Experience with Sleep Apnea
- Raising Health Awareness: Basketball legend Shaquille O'Neal partners with Eli Lilly to share his personal journey with moderate obstructive sleep apnea (OSA), aiming to raise public awareness about this health issue affecting approximately 24 million adults in the U.S. and encouraging more individuals to seek medical help.
- Significant Drug Efficacy: Zepbound® (tirzepatide), the first prescription medication for moderate-to-severe OSA, demonstrated in clinical studies that adults using the drug experienced a reduction in average breathing interruptions from 52.9 to 27.6 per hour over 52 weeks, significantly improving sleep quality and daily functioning.
- National Campaign Launch: Lilly has initiated the “Watch This” national campaign, leveraging O'Neal's authentic story across multiple channels to encourage individuals to recognize OSA symptoms and engage in discussions with their doctors, thereby increasing awareness and treatment rates for the condition.
- Community Engagement Plan: O'Neal plans to engage with communities through face-to-face interactions, sharing his struggles with OSA to help more people recognize potential health issues and motivate them to proactively seek medical advice.
See More
Tech Stock Pullback Sparks Market Attention
- Tech Stock Pullback: Over the last three trading days, tech stocks, particularly in semiconductors and AI, have faced significant declines, with the Nasdaq 100 dropping over 3% on July 24, 2024, indicating investor anxiety over AI investment returns, which could impact overall market confidence.
- Capex Concerns: For 2026, major hyperscalers are projected to guide capital expenditures between $600 billion and $700 billion, with Amazon alone forecasting $200 billion in infrastructure spending, a 56% increase, raising worries that cash flow may not support such high spending, potentially leading to further market turmoil.
- Shifting Market Sentiment: A strong employment report has pushed rate expectations higher, coupled with renewed fears over AI spending, causing market sentiment to shift from extreme bullishness to caution, leading to sell-offs at elevated levels and creating a negative feedback loop that may affect future investment decisions.
- Return to Defensive Investments: As capital flows out of tech, traditional defensive stocks like Eli Lilly, Home Depot, Procter & Gamble, and Starbucks are gaining attention, reflecting market confidence in economic health and potentially bringing much-needed capital into these previously overlooked sectors.
See More
Shaquille O'Neal Shares Experience with Sleep Apnea
- Raising Health Awareness: Basketball legend Shaquille O'Neal shares his personal journey with moderate obstructive sleep apnea (OSA), highlighting this health issue affecting approximately 24 million adults in the U.S., aiming to raise public awareness and encourage individuals to seek medical help.
- Innovative Medication: Eli Lilly introduces Zepbound® (tirzepatide), the first prescription medication for moderate to severe OSA, which should be used alongside a reduced-calorie diet and increased physical activity; clinical studies indicate it significantly reduces breathing interruptions during sleep, enhancing patients' quality of life.
- Significant Clinical Outcomes: In a 52-week study, adults taking Zepbound experienced a reduction in average breathing interruptions from 52.9 per hour to 27.6, demonstrating the drug's effectiveness in alleviating OSA symptoms, with 42.2% of patients achieving remission or mild OSA post-treatment.
- National Awareness Campaign: Lilly launches the “Watch This” national campaign, leveraging O'Neal's authentic story across multiple channels to help individuals recognize OSA symptoms and encourage them to communicate with their doctors, thereby promoting early diagnosis and treatment.
See More
Pfizer Reviews Investment Plans in Germany Amid Price Policy Changes
- Investment Review: Pfizer CEO Albert Bourla stated in a letter to Chancellor Friedrich Merz that the company is reviewing its investment timing and scope in Germany due to government proposals aimed at lowering drug prices, which could undermine long-term investment predictability in the pharmaceutical sector.
- Policy Impact: Bourla emphasized that the government's proposals raise questions about the predictability necessary for the pharmaceutical industry, prompting Pfizer to reassess its external engagements and future investment priorities, potentially affecting its market positioning in Germany.
- Industry Reaction: This announcement follows Eli Lilly's decision to halve its $2.3 billion investment in Germany and Boehringer Ingelheim's cancellation of its €900 million plans, both citing the government's healthcare cost-cutting measures, highlighting the industry's sensitivity to policy changes.
- Market Uncertainty: Pfizer's investment review reflects a broader uncertainty within the pharmaceutical industry regarding the future of the German market, which may lead other companies to reconsider their investment strategies in Germany, thereby impacting the overall investment climate in the sector.
See More
FDA Approves Ebglyss for Bi-Monthly Eczema Treatment
- Therapeutic Innovation: The FDA has approved Eli Lilly's Ebglyss for bi-monthly maintenance dosing, allowing patients to manage eczema with only six injections per year, significantly reducing treatment frequency and enhancing patient adherence and quality of life.
- Clinical Support: This approval is backed by data from the ADjoin late-stage trial extension, which evaluated Ebglyss administered every eight weeks versus every four weeks, demonstrating efficacy in patients with moderate-to-severe atopic dermatitis.
- Market Potential: The approval opens new market opportunities for Eli Lilly in dermatological treatments, particularly bolstered by its partnership with Spanish pharma company Almirall, enhancing its competitive position in the European market.
- Patient Benefit: Adrienne Brown, president of Lilly Immunology, noted that this therapy allows patients with moderate-to-severe atopic dermatitis to avoid starting with prescription topicals, greatly simplifying treatment regimens and addressing the demand for convenient therapies.
See More
FDA Approves New Dosing Regimen for EBGLYSS
- New Dosing Regimen: EBGLYSS (lebrikizumab-lbkz) has received FDA approval for a new regimen allowing a single 250 mg injection every eight weeks, reducing the treatment frequency to as few as six maintenance injections per year, significantly enhancing patient quality of life.
- Clinical Data Support: This approval is based on clinical data from the 32-week ADjoin long-term trial, demonstrating that the new dosing regimen maintains safety and efficacy comparable to the every-four-week schedule, ensuring sustained disease control for patients.
- Market Potential: As a first-line biologic treatment for moderate-to-severe atopic dermatitis, EBGLYSS is expected to attract more patients, further solidifying Lilly's market position in dermatological therapies.
- Patient Support Program: Lilly offers co-pay assistance through its EBGLYSS patient support services, ensuring that 94% of commercially insured patients have coverage, reflecting the company's commitment to health equity and affordability for patients.
See More
Shaquille O'Neal Shares Experience with Sleep Apnea
- Raising Health Awareness: Basketball legend Shaquille O'Neal partners with Eli Lilly to share his personal journey with moderate obstructive sleep apnea (OSA), aiming to raise public awareness about this health issue affecting approximately 24 million adults in the U.S. and encouraging more individuals to seek medical help.
- Significant Drug Efficacy: Zepbound® (tirzepatide), the first prescription medication for moderate-to-severe OSA, demonstrated in clinical studies that adults using the drug experienced a reduction in average breathing interruptions from 52.9 to 27.6 per hour over 52 weeks, significantly improving sleep quality and daily functioning.
- National Campaign Launch: Lilly has initiated the “Watch This” national campaign, leveraging O'Neal's authentic story across multiple channels to encourage individuals to recognize OSA symptoms and engage in discussions with their doctors, thereby increasing awareness and treatment rates for the condition.
- Community Engagement Plan: O'Neal plans to engage with communities through face-to-face interactions, sharing his struggles with OSA to help more people recognize potential health issues and motivate them to proactively seek medical advice.
See More
Tech Stock Pullback Sparks Market Attention
- Tech Stock Pullback: Over the last three trading days, tech stocks, particularly in semiconductors and AI, have faced significant declines, with the Nasdaq 100 dropping over 3% on July 24, 2024, indicating investor anxiety over AI investment returns, which could impact overall market confidence.
- Capex Concerns: For 2026, major hyperscalers are projected to guide capital expenditures between $600 billion and $700 billion, with Amazon alone forecasting $200 billion in infrastructure spending, a 56% increase, raising worries that cash flow may not support such high spending, potentially leading to further market turmoil.
- Shifting Market Sentiment: A strong employment report has pushed rate expectations higher, coupled with renewed fears over AI spending, causing market sentiment to shift from extreme bullishness to caution, leading to sell-offs at elevated levels and creating a negative feedback loop that may affect future investment decisions.
- Return to Defensive Investments: As capital flows out of tech, traditional defensive stocks like Eli Lilly, Home Depot, Procter & Gamble, and Starbucks are gaining attention, reflecting market confidence in economic health and potentially bringing much-needed capital into these previously overlooked sectors.
See More
Shaquille O'Neal Shares Experience with Sleep Apnea
- Raising Health Awareness: Basketball legend Shaquille O'Neal shares his personal journey with moderate obstructive sleep apnea (OSA), highlighting this health issue affecting approximately 24 million adults in the U.S., aiming to raise public awareness and encourage individuals to seek medical help.
- Innovative Medication: Eli Lilly introduces Zepbound® (tirzepatide), the first prescription medication for moderate to severe OSA, which should be used alongside a reduced-calorie diet and increased physical activity; clinical studies indicate it significantly reduces breathing interruptions during sleep, enhancing patients' quality of life.
- Significant Clinical Outcomes: In a 52-week study, adults taking Zepbound experienced a reduction in average breathing interruptions from 52.9 per hour to 27.6, demonstrating the drug's effectiveness in alleviating OSA symptoms, with 42.2% of patients achieving remission or mild OSA post-treatment.
- National Awareness Campaign: Lilly launches the “Watch This” national campaign, leveraging O'Neal's authentic story across multiple channels to help individuals recognize OSA symptoms and encourage them to communicate with their doctors, thereby promoting early diagnosis and treatment.
See More
Pfizer Reviews Investment Plans in Germany Amid Price Policy Changes
- Investment Review: Pfizer CEO Albert Bourla stated in a letter to Chancellor Friedrich Merz that the company is reviewing its investment timing and scope in Germany due to government proposals aimed at lowering drug prices, which could undermine long-term investment predictability in the pharmaceutical sector.
- Policy Impact: Bourla emphasized that the government's proposals raise questions about the predictability necessary for the pharmaceutical industry, prompting Pfizer to reassess its external engagements and future investment priorities, potentially affecting its market positioning in Germany.
- Industry Reaction: This announcement follows Eli Lilly's decision to halve its $2.3 billion investment in Germany and Boehringer Ingelheim's cancellation of its €900 million plans, both citing the government's healthcare cost-cutting measures, highlighting the industry's sensitivity to policy changes.
- Market Uncertainty: Pfizer's investment review reflects a broader uncertainty within the pharmaceutical industry regarding the future of the German market, which may lead other companies to reconsider their investment strategies in Germany, thereby impacting the overall investment climate in the sector.
See More
FDA Approves Ebglyss for Bi-Monthly Eczema Treatment
- Therapeutic Innovation: The FDA has approved Eli Lilly's Ebglyss for bi-monthly maintenance dosing, allowing patients to manage eczema with only six injections per year, significantly reducing treatment frequency and enhancing patient adherence and quality of life.
- Clinical Support: This approval is backed by data from the ADjoin late-stage trial extension, which evaluated Ebglyss administered every eight weeks versus every four weeks, demonstrating efficacy in patients with moderate-to-severe atopic dermatitis.
- Market Potential: The approval opens new market opportunities for Eli Lilly in dermatological treatments, particularly bolstered by its partnership with Spanish pharma company Almirall, enhancing its competitive position in the European market.
- Patient Benefit: Adrienne Brown, president of Lilly Immunology, noted that this therapy allows patients with moderate-to-severe atopic dermatitis to avoid starting with prescription topicals, greatly simplifying treatment regimens and addressing the demand for convenient therapies.
See More
